NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.21

+0.01 (+0.45%)

(As of 03/24/2023 02:14 PM ET)

Add

Compare

Today's Range: $2.17
▼
$2.25
50-Day Range: $1.95
▼
$2.52
52-Week Range: $1.89
▼
$3.18

Volume: 4,161 shs
Average Volume: 27,787 shs
Market Capitalization: $108.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

MediciNova MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.30) to ($0.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.92 out of 5 stars

Medical Sector

984th out of 989 stocks

Pharmaceutical Preparations Industry

477th out of 480 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for MediciNova.

3.0

Short Interest

Percentage of Shares Shorted
0.78% of the float of MediciNova has been sold short.
Short Interest Ratio / Days to Cover
MediciNova has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in MediciNova has recently decreased by 0.19%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
MediciNova does not currently pay a dividend.
Dividend Growth
MediciNova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNOV.

1.7

News and Social Media Coverage

News Sentiment
MediciNova has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MediciNova this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added MediciNova to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediciNova insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.70% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 25.18% of the stock of MediciNova is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MediciNova are expected to decrease in the coming year, from ($0.30) to ($0.34) per share.
Price to Book Value per Share Ratio
MediciNova has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

March 22, 2023 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) & Enlivex Therapeutics (NASDAQ:ENLV) Head-To-Head Contrast

March 20, 2023 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com

March 24, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

March 9, 2023 | finance.yahoo.com

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

February 27, 2023 | finance.yahoo.com

MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…

February 20, 2023 | finance.yahoo.com

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

February 8, 2023 | finance.yahoo.com

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

January 30, 2023 | finance.yahoo.com

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

March 24, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

January 12, 2023 | finance.yahoo.com

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

January 11, 2023 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

January 9, 2023 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

January 5, 2023 | finance.yahoo.com

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

December 6, 2022 | finance.yahoo.com

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

December 5, 2022 | finance.yahoo.com

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

November 18, 2022 | finance.yahoo.com

MNOV: Well Financed to Get Through Tough Market Conditions…

October 13, 2022 | finance.yahoo.com

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

October 6, 2022 | reuters.com

MNOV.A - MediciNova, Inc. | Stock Price & Latest News | Reuters

September 29, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

September 16, 2022 | seekingalpha.com

MediciNova to get US patent for MN-166 to treat brain cancer - Seeking Alpha

September 15, 2022 | globenewswire.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire

September 15, 2022 | finance.yahoo.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

September 15, 2022 | globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswire

September 14, 2022 | nasdaq.com

Health Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - Nasdaq

September 14, 2022 | finance.yahoo.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

September 14, 2022 | seekingalpha.com

MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders

September 14, 2022 | finance.yahoo.com

MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings: 10/26/2020
Today: 3/24/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNOV
CUSIP: N/A
CIK: 1226616
Web: medicinova.com
Phone: (858) 373-1500
Fax: 858-404-0048
Employees: 11
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,060,000.00
Net Margins: N/A
Pretax Margin: -2,628,577.25%
Return on Equity: -18.73%
Return on Assets: -17.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.51
Quick Ratio: 18.51

Sales & Book Value

Annual Sales: $4.04 million
Price / Sales: 26.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.43 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 49,050,000
Free Float: 40,855,000
Market Cap: $107.42 million
Optionable: Optionable
Beta: 0.98

Social Links

Key Executives

Yuichi Iwaki
President, Chief Executive Officer & Director

Jason Kruger
Chief Financial Officer

Kazuko Matsuda
Director & Chief Medical Officer

Geoffrey G. O'Brien
Vice President & Executive Officer

David H. Crean
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.
How have MNOV shares performed in 2023?: MediciNova's stock was trading at $2.05 at the beginning of 2023. Since then, MNOV shares have increased by 6.8% and is now trading at $2.19.
View the best growth stocks for 2023 here.
When is MediciNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our MNOV earnings forecast.
How were MediciNova's earnings last quarter?: MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04.
What other stocks do shareholders of MediciNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?: MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
Who are MediciNova's major shareholders?: MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.89%), Jane Street Group LLC (0.55%), Millennium Management LLC (0.51%), JPMorgan Chase & Co. (0.51%), HRT Financial LP (0.37%) and Bank of America Corp DE (0.36%).
View institutional ownership trends.
How do I buy shares of MediciNova?: Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MediciNova's stock price today?: One share of MNOV stock can currently be purchased for approximately $2.19.
How much money does MediciNova make?: MediciNova (NASDAQ:MNOV) has a market capitalization of $107.42 million and generates $4.04 million in revenue each year.
How can I contact MediciNova?: MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MediciNova - MNOV Stock Forecast, Price & News

MediciNova MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MediciNova (NASDAQ:MNOV) Stock

MNOV Stock News Headlines

MNOV Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MNOV Stock - Frequently Asked Questions

Overall MarketRank^™